Solar Foods (SFOODS) H2 2024 earnings summary

Executive summary

• Factory 01 began operations in April 2024, marking a key milestone in scaling Solein production and proving technology scalability.

• Achieved US regulatory approval (self-affirmed GRAS status), enabling commercial activities in the US and supporting a strategic focus on Health & Performance Nutrition.

• Company listed on Nasdaq First North in September 2024 to support global growth ambitions and capital access.

• Significant management changes, including appointment of new CEO Rami Jokela and expansion of the management team.

• Reviewed strategy for 2025–2030 focuses on US Health & Performance Nutrition, higher price points, and capacity expansion.

Financial highlights

• Full-year operating loss was EUR 8.9 million to EUR 11 million, with July–December loss at EUR 4.6 million, reflecting increased OpEx from Factory 01 and listing expenses.

• Loss for the period was EUR 11 million (EUR 9 million prior year); no revenue recognized as company remains in early commercialization.

• Year-end cash and cash equivalents stood at EUR 13.4 million (down from EUR 16.4 million); equity ratio at 50%.

• Investments totaled up to EUR 9.1 million, mainly in Factory 01 and development.

• Personnel increased to 53 from 31 year-over-year, reflecting scaling operations.

Outlook and guidance

• Initial revenue expected in 2025–26 with US go-to-market from Factory 01; profitability targeted for 2027–30 with Factory 02 and customer base expansion.

• Long-term target is positive EBITDA by 2030, driven by higher prices, new markets, and productivity gains.

• Factory 01 capacity to expand from 160 to 230 tons by 2026; phased investment plan for Factory 02 underway.

• Financing estimated to cover business needs for at least 12 months; no dividend expected in the short to medium term.

• EUR 10 million Business Finland grant awarded for R&D and US go-to-market activities, extending through 2026.